Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Bionano Genomics's operating assets for the quarter that ended in Jun. 2026 was MXN657.3 Mil. Bionano Genomics's operating liabilities for the quarter that ended in Jun. 2026 was MXN161.9 Mil. Bionano Genomics's Total Assets for the quarter that ended in Mar. 2026 was MXN1,168.6 Mil. Therefore, Bionano Genomics's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2026 was 0.42.
Bionano Genomics Scaled Net Operating Assets Related Terms
Bionano Genomics Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Bionano Genomics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics Scaled Net Operating Assets Chart
MEX:BNGO vs RGNT, UEEC, FEMY: Scaled Net Operating Assets Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.42 mean?
Bionano Genomics (MEX:BNGO) has a Scaled Net Operating Assets of 0.42 as of Jun. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Bionano Genomics and its competitors.
Is Bionano Genomics' Scaled Net Operating Assets too high?
Bionano Genomics' current Scaled Net Operating Assets is 0.42. Overall, Bionano Genomics has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' Scaled Net Operating Assets compare to RGNT and UEEC?
Bionano Genomics' Scaled Net Operating Assets of 0.42 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Bionano Genomics and its competitors. Bionano Genomics's current Scaled Net Operating Assets is 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN16.20, compared to a current price of MXN21.00 — trading 29.6% above its estimated fair value. The current Scaled Net Operating Assets is 0.42. Bionano Genomics' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current Scaled Net Operating Assets is 0.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be overvalued.
The current stock price of MXN21.00 is trading 29.6% above its estimated GF Value™ of MXN16.20.
GuruFocus considers Bionano Genomics to be Modestly Overvalued.
Key valuation signals for MEX:BNGO:
Scaled Net Operating Assets: 0.42
GF Value™: MXN16.20 vs. price of MXN21.00 (29.6% above fair value)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
62GF Score
Get the complete analysis for MEX:BNGO
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
